AllPennyStocks.com News: DelMar Pharmaceuticals Reports Q2 Results, Provides Corporate Update

Mississauga, ON -- (SBWIRE) -- 02/16/2016 -- AllPennyStocks.com Media, Inc. (http://www.AllPennyStocks.com/) announces its latest article titled "DelMar Pharmaceuticals Reports Q2 Results, Provides Corporate Update."

Companies mentioned in this article include iShares NASDAQ Biotechnology Index (ETF) (NASDAQ:IBB) and DelMar Pharmaceuticals Inc. (OTCQX:DMPI).

Article Excerpt:

The iShares NASDAQ Biotechnology Index (ETF) (NASDAQ:IBB) has bounced back sharply in the last two trading sessions. The ETF closed almost 3% higher on Friday. In mid-day trading today, it has gained another 2.2%.

The sharp rebound in the biotech focused ETF has come as market sentiment has improved over the weekend. Investors' sentiment got a boost after the European Central Bank (ECB) President Mario Draghi hinted at further stimulus measures. Sentiment got a further boost after major oil producers agreed to a production freeze, a move that could provide a floor to oil prices. As investors once again move into risk assets, one of the beneficiaries has been the biotechnology sector.

One of the major movers in the biotech sector today is DelMar Pharmaceuticals Inc. (OTCQX:DMPI), which has offices in Vancouver and Menlo Park, California. DMPI is focused on the development and commercialization of new cancer therapies in indications where patients are failing or have become intolerable to modern targeted or biologic treatments. DMPI shares were last trading at $0.809, up 5.06%.

The full version of this article can be found at:
http://www.allpennystocks.com/aps_us/special-reports/613/delmar-pharmaceuticals-reports-q2-results-provides-corporate-update.htm

About AllPennyStocks.com
AllPennyStocks.com is focused on the small-cap / penny stock market and has become a reputable name in the investment community. AllPennyStocks.com runs a Canadian and US site to provide investors in Canada as well as the United States with informative and unique content and information. AllPennyStocks.com runs daily technical penny stocks to watch, has a daily market write-up, provides company spotlights, runs unique most active pages strictly for penny stocks trading on the TSX, TSX Venture, NASDAQ and OTC BB, and much more information for the average investor.

AllPennyStocks.com also runs an email newsletter that aims to uncover stocks that are still under the radar of most investors. Criteria AllPennyStocks.com looks for includes strong revenues, a seasoned management, innovative business plans, among many others. AllPennyStocks.com also looks for companies that announce breaking news, recent 52-week highs/lows, technical breakouts, and other favorable corporate information.

Investors are encouraged to subscribe to the AllPennyStocks.com FREE e-mail newsletter and see what tens of thousands of other investors have already been receiving since 1999.

Investors can receive their free newsletter subscription by clicking here:
http://www.allpennystocks.com/aps_common/newsletter_free.asp

Contact:
AllPennyStocks.com Media, Inc.
Peter Szafranski -- President
Phone: 905-361-5680
E-Mail: peter@allpennystocks.com
Websites: http://www.allpennystocks.com / http://www.bullishinvestor.com

Note: AllPennyStocks.com has not received compensation for carrying the above-mentioned company; a full disclaimer can be viewed here: http://www.allpennystocks.com/aps_common/disclaimer.asp

For more information on this press release visit: http://www.sbwire.com/press-releases/allpennystockscom-news-delmar-pharmaceuticals-reports-q2-results-provides-corporate-update-665590.htm